Intalight™ Secures CE Mark for Innovative DREAM OCT™ Imaging Platform

Intalight™ Achieves CE Mark for DREAM OCT™ Imaging

Intalight™, a front-runner in the field of ophthalmic technology, has recently declared that it has received the CE marking for its innovative DREAM OCT™ platform. This pivotal approval from the European Union allows the marketing and distribution of its state-of-the-art imaging device. The DREAM in DREAM OCT stands for several key attributes: Deep imaging depth, Rapid scanning speed, Extensive scan area, Accurate results, and Multimodal imaging capabilities. This platform is designed to deliver the highest quality Optical Coherence Tomography (OCT) images available today.

Shawn Peng, the Chairman and Founder of Intalight, expressed immense pride in achieving this milestone, emphasizing how it empowers ophthalmologists across Europe with cutting-edge technology that can significantly enhance patient outcomes. The DREAM OCT is capable of covering an ultra-wide field in a single scan, providing a striking 130° OCTA image. Its 12 mm super-depth scan feature harnesses swept-source technology, ensuring exquisite imaging of the choroid, retina, and a significant portion of the vitreous body. Notably, its super-depth scan function for the anterior segment reaches an impressive 16.2 mm in air, enabling comprehensive scanning from the cornea to the anterior part of the vitreous in just one scan.

One of the device's remarkable benefits is its longer wavelength which allows for better penetration through opacities in the lens or vitreous gel. Bing Li, Co-Founder and Managing Director of Intalight, highlighted that feedback from ophthalmologists and optometrists had pointed to the need for a solution capable of executing imaging tasks quickly and reliably. The DREAM OCT fulfills this demand edge by offering a comprehensive range of imaging procedures tailored for demanding clinical and scientific applications in retinal care, surpassing the capabilities of existing devices that specialists are familiar with.

Developed using groundbreaking Ultra-Wide Swept-Source technology, the DREAM OCT addresses the needs of retinal specialists and general ophthalmologists, enabling them to obtain highly detailed imaging necessary for improved care and outcomes. The results obtained from the DREAM OCT are already featured in over 160 peer-reviewed studies, underscoring its credibility in the medical community.

Commenting on the significance of this milestone, Joe Garibaldi, Intalight’s Sales Director, stated, “This is thrilling news for Intalight! Now, we do not have to wait any longer in Europe, and we are looking forward to providing this innovative solution to the US market as well.” Intalight is keen to expand its renowned network of global institutions and ophthalmologists, leveraging not only the recent CE approval but also anticipating FDA approval in the future.

As a clinically validated leader in the ultra-wide field OCTA sector, Intalight is collaborating with top academic retina institutions and private retina practices in the United States, Europe, and Asia to enhance patient care. Founded by a group of scientists and industry veterans from Silicon Valley, Intalight Inc. aims to develop advanced ophthalmology technologies. With operational bases in the Silicon Valley, Shanghai, and Luoyang, its Optical Coherence Tomography device, known as DREAM OCT™, employs advanced imaging capabilities combining depth, speed, and accuracy, making it an essential tool for ophthalmologists in both clinical environments and research settings.

For further information on Intalight and their innovative DREAM OCT imaging device, visit their official website at Intalight. Stay connected by following us on LinkedIn and Facebook for the latest updates and developments in ophthalmic technology.